Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.
Chin Med J (Engl). 2010 Oct;123(19):2655-61.
There are numerous articles on the endothelial progenitor cells (EPCs) in different disease conditions. However, the functional properties of EPCs in acute coronary syndrome (ACS) are still uncertain. Here we aimed to study the number and functions of EPCs in ACS patients.
Patients were enrolled with admitted ACS (n = 25) and another 25 gender-, age-, atherosclerotic risk factors-matched stable coronary artery disease (CAD) controls. EPCs were defined as CD34(+)/CD133(+)/VEGFR-2(+) and quantified by flow cytometry. Moreover, functional properties of EPCs including colony-forming unit (CFU), proliferation, migration as well as apoptosis were evaluated and compared between the two groups. Plasma matrix metalloproteinase-9 (MMP-9) was detected in all patients as well.
The two groups had similar medication and clinical characteristics on admission. The EPCs in ACS patients were more than 2.6 times that in stable CAD subjects (15.6 ± 2.7 vs. 6.0 ± 0.8/100 000 events, P < 0.01). CFU was not statistically different between the two groups (10.8 ± 2.9 vs. 8.2 ± 1.8, number/well, P > 0.05). Furthermore, EPCs isolated from ACS patients were significantly impaired in their proliferation (0.498 ± 0.035 vs. 0.895 ± 0.067, OD value, P < 0.01) and migration capacity (20.5 ± 3.4 vs. 30.7 ± 4.3, number/well, P < 0.01) compared with controls. Moreover, the apoptosis cell in cultured EPCs was drastically increased in ACS group ((18.3 ± 2.1)% vs. (7.8 ± 0.4)%, P < 0.01).
Patients with ACS exhibited apparently increased circulating EPCs as well as cultured apoptosis percentage together with a remarkable impairment of proliferation and migration activities compared with stable CAD subjects.
已有大量关于不同疾病状态下内皮祖细胞（EPCs）的文章。然而，急性冠状动脉综合征（ACS）患者中 EPC 的功能特性仍不确定。在此，我们旨在研究 ACS 患者中 EPC 的数量和功能。
纳入 ACS 患者（n=25）和 25 名性别、年龄、动脉粥样硬化危险因素匹配的稳定型冠状动脉疾病（CAD）对照。通过流式细胞术将 EPC 定义为 CD34(+)/CD133(+)/VEGFR-2(+)，并进行定量分析。此外，还评估和比较了两组之间 EPC 的集落形成单位（CFU）、增殖、迁移和凋亡等功能特性。所有患者均检测血浆基质金属蛋白酶-9（MMP-9）。
两组入院时的药物和临床特征相似。ACS 患者的 EPC 数量是稳定 CAD 患者的 2.6 倍以上（15.6±2.7 vs. 6.0±0.8/100000 个事件，P<0.01）。两组 CFU 无统计学差异（10.8±2.9 vs. 8.2±1.8，每孔数量，P>0.05）。此外，ACS 患者分离的 EPC 增殖能力（0.498±0.035 vs. 0.895±0.067，OD 值，P<0.01）和迁移能力（20.5±3.4 vs. 30.7±4.3，每孔数量，P<0.01）明显受损。此外，培养的 EPC 中的凋亡细胞在 ACS 组中明显增加（（18.3±2.1）% vs. （7.8±0.4）%，P<0.01）。
与稳定型 CAD 患者相比，ACS 患者的循环 EPC 明显增加，培养的凋亡率明显增加，增殖和迁移活性明显受损。
